Drug Profile
SBT 104
Alternative Names: SBT 104Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Singh Biotechnology
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Single-domain antibodies
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA
- 28 May 2023 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA
- 28 Nov 2021 No recent reports of development identified for preclinical development in Psoriasis in USA